Glenmark may return 20-22% on target 370-380: Anagram Capital

A quick word from you on the pharmaceutical space right now...

Avinash Gorakshekar: I would be a buyer on may be Ranbaxy and may be a Glenmark because we feel that the kind of traction one has actually seen in the last couple of quarters. Going forward also our sense is that in a kind of a volatile and a kind of a choppy environment, these companies would definitely give a kind of a good top line as well as a bottom line growth of roughly about 15-20%.

In fact Glenmark has also corrected quite sharply and our in-house view is that over the next say 12-15 months, this stock can definitely give you a good return of about 20-22% with a target price of roughly about 370-380 but definitely today has not been a good day but nevertheless the prospects for both these companies, Ranbaxy and a Glenmark look quite positive